Gut-directed therapeutics in inflammatory bowel disease., PMID:40305008
Gut-directed therapeutics in inflammatory bowel disease., PMID:40305008
Mucosal Addressin Cell Adhesion Molecule-1 Mediates T Cell Migration into Pancreas-Draining Lymph Nodes for Initiation of the Autoimmune Response in Type 1 Diabetes., PMID:39518902
Mucosal Addressin Cell Adhesion Molecule-1 Mediates T Cell Migration into Pancreas-Draining Lymph Nodes for Initiation of the Autoimmune Response in Type 1 Diabetes., PMID:39518902
Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer., PMID:39438458
Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer., PMID:39438458
Predictors of the efficacy of vedolizumab in patients with ulcerative colitis., PMID:39355361
Predictors of the efficacy of vedolizumab in patients with ulcerative colitis., PMID:39355361
miR-200c-3p regulates α4 integrin-mediated T cell adhesion and migration., PMID:38936759
miR-200c-3p regulates α4 integrin-mediated T cell adhesion and migration., PMID:38936759
MAdCAM-1 co-stimulation combined with retinoic acid and TGF-β induces blood CD8+ T cells to adopt a gut CD101+ TRM phenotype., PMID:38729611
MAdCAM-1 co-stimulation combined with retinoic acid and TGF-β induces blood CD8+ T cells to adopt a gut CD101+ TRM phenotype., PMID:38729611
Selective Targeting of α4β7/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver., PMID:38727292
Selective Targeting of α4β7/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver., PMID:38727292
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis., PMID:38640252
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis., PMID:38640252
Intestinal MAdCAM-1 imaging as biomarker for prognostic in murine models of multiple sclerosis., PMID:38604270
Intestinal MAdCAM-1 imaging as biomarker for prognostic in murine models of multiple sclerosis., PMID:38604270
Vedolizumab Does Not Affect Antibody Secreting Cell Recruitment to the Lactating Mammary Gland of Mothers With Inflammatory Bowel Disease., PMID:38334263
Vedolizumab Does Not Affect Antibody Secreting Cell Recruitment to the Lactating Mammary Gland of Mothers With Inflammatory Bowel Disease., PMID:38334263
NGFR regulates stromal cell activation in germinal centers., PMID:38307025
NGFR regulates stromal cell activation in germinal centers., PMID:38307025
Blocking GPR15 Counteracts Integrin-dependent T Cell Gut Homing in Vivo., PMID:38243565
Blocking GPR15 Counteracts Integrin-dependent T Cell Gut Homing in Vivo., PMID:38243565
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease., PMID:38096402
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease., PMID:38096402
The Force-Dependent Mechanism of an Integrin α4β7-MAdCAM-1 Interaction., PMID:38003252
The Force-Dependent Mechanism of an Integrin α4β7-MAdCAM-1 Interaction., PMID:38003252
Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells., PMID:37837660
Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells., PMID:37837660
Machine Learning-Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical Trials., PMID:37828747
Machine Learning-Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical Trials., PMID:37828747
MAdCAM-1 targeting strategy can prevent colitic cancer carcinogenesis and progression via suppression of immune cell infiltration and inflammatory signals., PMID:37676657
MAdCAM-1 targeting strategy can prevent colitic cancer carcinogenesis and progression via suppression of immune cell infiltration and inflammatory signals., PMID:37676657
An update on the safety of long-term vedolizumab use in inflammatory bowel disease., PMID:37610086
An update on the safety of long-term vedolizumab use in inflammatory bowel disease., PMID:37610086
Gut-licensed β7+ CD4+ T cells contribute to progressive retinal ganglion cell damage in glaucoma., PMID:37531415
Gut-licensed β7+ CD4+ T cells contribute to progressive retinal ganglion cell damage in glaucoma., PMID:37531415
Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis., PMID:37436917
Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis., PMID:37436917
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers., PMID:37289890
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers., PMID:37289890
Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease., PMID:37208197
Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease., PMID:37208197
A pediatric case of infliximab-resistant ulcerative colitis successfully treated using vedolizumab., PMID:37164738
A pediatric case of infliximab-resistant ulcerative colitis successfully treated using vedolizumab., PMID:37164738
Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies., PMID:37130727
Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies., PMID:37130727
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing., PMID:37029786
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing., PMID:37029786
Salmonella infection induces the reorganization of follicular dendritic cell networks concomitant with the failure to generate germinal centers., PMID:36950118
Salmonella infection induces the reorganization of follicular dendritic cell networks concomitant with the failure to generate germinal centers., PMID:36950118
The Underappreciated Role of Secretory IgA in IBD., PMID:36943800
The Underappreciated Role of Secretory IgA in IBD., PMID:36943800
Cost effective and reliable cell based ELISA as an alternative method of flow cytometry for assessment of binding activity of Vedolizumab., PMID:36865445
Cost effective and reliable cell based ELISA as an alternative method of flow cytometry for assessment of binding activity of Vedolizumab., PMID:36865445
Selective targeting of α 4 β 7 /MAdCAM-1 axis suppresses liver fibrosis by reducing proinflammatory T cell recruitment to the liver., PMID:36865167
Selective targeting of α 4 β 7 /MAdCAM-1 axis suppresses liver fibrosis by reducing proinflammatory T cell recruitment to the liver., PMID:36865167
MAdCAM-1 does not play a central role in the early pathophysiology of autoimmune hepatitis., PMID:36841352
MAdCAM-1 does not play a central role in the early pathophysiology of autoimmune hepatitis., PMID:36841352
Intestinal Barrier Dysfunction and Microbial Translocation in Patients with First-Diagnosed Atrial Fibrillation., PMID:36672684
Intestinal Barrier Dysfunction and Microbial Translocation in Patients with First-Diagnosed Atrial Fibrillation., PMID:36672684
Fibroblastic reticular cells orchestrate long-term graft survival following recipient treatment with CD40 ligand-targeted costimulatory blockade., PMID:36519546
Fibroblastic reticular cells orchestrate long-term graft survival following recipient treatment with CD40 ligand-targeted costimulatory blockade., PMID:36519546
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease., PMID:36272713
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease., PMID:36272713
Dach1 transcription factor regulates the expression of peripheral node addressin and lymphocyte trafficking in lymph nodes., PMID:36045707
Dach1 transcription factor regulates the expression of peripheral node addressin and lymphocyte trafficking in lymph nodes., PMID:36045707
Serological biomarkers for management of primary sclerosing cholangitis., PMID:35800183
Serological biomarkers for management of primary sclerosing cholangitis., PMID:35800183
Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis., PMID:35784193
Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis., PMID:35784193
Targeting TLR4 during vaccination boosts MAdCAM-1+ lymphoid stromal cell activation and promotes the aged germinal center response., PMID:35522725
Targeting TLR4 during vaccination boosts MAdCAM-1+ lymphoid stromal cell activation and promotes the aged germinal center response., PMID:35522725
Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro., PMID:35349682
Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro., PMID:35349682
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis., PMID:34868349
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis., PMID:34868349
Alterations in MAdCAM1-Positive Mucosal Capillaries and Integrin a4b7-Positive Lymphocytes in Crohn's Disease Treated with Anti-TNFα Biologics., PMID:34686510
Alterations in MAdCAM1-Positive Mucosal Capillaries and Integrin a4b7-Positive Lymphocytes in Crohn's Disease Treated with Anti-TNFα Biologics., PMID:34686510
Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis., PMID:34584975
Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis., PMID:34584975
Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis., PMID:34433904
Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis., PMID:34433904
sMAdCAM: IL-6 Ratio Influences Disease Progression and Anti-Viral Responses in SARS-CoV-2 Infection., PMID:34194420
sMAdCAM: IL-6 Ratio Influences Disease Progression and Anti-Viral Responses in SARS-CoV-2 Infection., PMID:34194420
Optogenetic activation of local colonic sympathetic innervations attenuates colitis by limiting immune cell extravasation., PMID:33932356
Optogenetic activation of local colonic sympathetic innervations attenuates colitis by limiting immune cell extravasation., PMID:33932356
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study., PMID:33880650
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study., PMID:33880650
Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms., PMID:33837762
Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms., PMID:33837762
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II., PMID:33599720
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II., PMID:33599720
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations., PMID:33245363
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations., PMID:33245363
Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease., PMID:33173291
Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease., PMID:33173291
Ultrasensitive molecular imaging of intestinal mucosal inflammation using leukocyte-mimicking particles targeted to MAdCAM-1 in mice., PMID:32908005
Ultrasensitive molecular imaging of intestinal mucosal inflammation using leukocyte-mimicking particles targeted to MAdCAM-1 in mice., PMID:32908005
For research use only. Not for human or drug use.
